Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Retrieved on:
Thursday, March 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, OPEX, ACOR, SG, Therapy, GAAP, Esteve, EBITDA, Government, Alkermes, Biotie Therapies, R, Acorda Therapeutics, Catalent, Cryptocurrency, Pharmaceutical industry, Video game, Reinsurance, Clothing, Music, Bookkeeping, Biogen, Açorda, 4-Aminopyridine, Nepicastat
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
Key Points:
- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
- “Acorda’s operating and financial performance improved throughout the year, meeting our financial guidance for 2022 AMPYRA net revenue, INBRIJA U.S. net revenue, cash, and adjusted OPEX.
- For the quarter ended December 31, 2022, the Company reported AMPYRA net revenue of $18.8 million, a 16.6% decrease compared to the same quarter in 2021.
- Additionally, for the quarter ended December 31, 2022, the Company reported FAMPYRA royalty revenues of $2.7 million, a 25.1% decrease compared to the same quarter in 2021.